Savara Inc. to Highlight Advances in Rare Lung Disease Research at ATS 2024

Medical/Healthcare News© Jae Young Ju / Getty Images / Canva

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company focused on rare respiratory diseases, is set to present groundbreaking research at the upcoming American Thoracic Society (ATS) 2024 International Conference in San Diego, CA, from May 17-22, 2024. The company announced the acceptance of two critical abstracts for poster presentation, emphasizing the healthcare burden of Pulmonary Alveolar Proteinosis (PAP) and the development of a novel diagnostic test for the disease.

Pulmonary Alveolar Proteinosis, a rare and chronic lung condition characterized by the accumulation of surfactant within the alveoli, poses significant diagnostic and treatment challenges. Matt Pauls, Chair and CEO of Savara, expressed the company’s eagerness to share their findings, particularly the development of a laboratory-based autoantibody blood test designed to offer a definitive diagnosis of autoimmune PAP (aPAP), the most common form of the disease.

The presentations, scheduled for May 19, will delve into the healthcare burden faced by patients with PAP and showcase a pioneering laboratory test for detecting GM-CSF antibodies, a marker for aPAP. This advancement stands to significantly aid in diagnosing individuals at risk, potentially improving patient outcomes through earlier and more accurate detection.

In addition to the poster sessions, Savara will host an Industry Theater featuring experts Bruce Trapnell, M.D., M.S., and Tisha Wang, M.D., who will discuss the pathophysiology, diagnosis, and management of PAP. This session aims to enhance awareness and understanding of aPAP among healthcare professionals, highlighting the disease’s impact and the journey toward accurate diagnosis.

This focus on PAP at the ATS 2024 Conference highlights the ongoing need for research and innovation in the diagnosis and treatment of rare lung diseases. By presenting these findings, Savara Inc. contributes to the broader medical community’s efforts to address the challenges associated with rare respiratory conditions, offering hope for improved patient care and outcomes.

READ:  Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.